Patients in the chronic phase (CP) of chronic myelogenous leukemia (CML) have been treated successfully following the advent of ABL kinase inhibitors. but once they progress to the blast crisis (BC) phase the prognosis becomes dismal. Although mechanisms underlying the progression are largely unknown. recent studies revealed the presence of alterations of key molecules for hematopoiesis. https://jalyttlers.shop/product-category/chandelier/